Through its discovery platform, Octagon can identify metabolic processes that drive the rapid proliferation of disease-causing cells. These drug targets have been extensively validated and form the basis for development programs in several disease areas.
OTG-W91 is a potent and selective inhibitor of B-cell proliferation. This program has the potential to treat serious B-cell driven autoimmune diseases, either as a monotherapy or in combination with best-in-class biologics.
OTG005 has demonstrated compelling effectiveness against infections caused by Acinetobacter baumannii and Pseudomonas aeruginosa in animal models and has previously been shown to be safe in humans. OTG005 is effective against bacteria that are resistant to all other antibiotic classes. Octagon is exploring the potential of this medicine to address resistant pulmonary infections in patients with Cystic Fibrosis.
Cancerous cells have reprogrammed metabolic processes and altered nutrient requirements. Octagon’s discovery platform holds significant promise in identifying novel drug targets involved in cancer cell proliferation.